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An area of T1 hyperintensity is normally observed in the posterior part of the sella turcica on MR im-ages of the brain. This phenomenon, often referred 
to as the pituitary bright spot (PBS), is thought to result 
from the T1-shortening effect of stored vasopressin in the 
posterior lobe of the pituitary1,12 and is observed in 100% 
of children15,17 and in 52% to 100% of adults5,6,8,19,22 without 
pituitary disease. The PBS may be absent in up to 48% of 
normal subjects, more often in older patients.5,23 Individu-
al variations in the appearance of the PBS have been ob-
served. Physiological conditions such as very young age, 
pregnancy, or lactation may result in an enlarged PBS.2
An abnormal PBS can also be seen in various patho-
logical processes. Central diabetes insipidus (DI) results 
from low blood levels of vasopressin and may be primary 
or secondary to a number of causes. In primary central 
DI, the PBS has been found to be absent in 25% to 100% 
of cases.12,15,17 Secondary central DI is a feature of Langer-
hans cell histiocytosis, germinoma, teratoma, craniopha-
ryngioma, idiopathic giant cell granulomatous hypophy-
sitis, and Wolfram syndrome. When DI was a presenting 
symptom of one of these conditions, the PBS was always 
absent.7,9,12,15,17,18 In conditions in which the posterior pi-
tuitary is depleted of its vasopressin granules, the hyper-
intense T1 signal can also be lost. An absent PBS was 
observed in 32% of patients with uncontrolled diabetes 
mellitus11 and in a patient with severe anorexia nervosa.21 
Finally, when the pituitary stalk is interrupted, the vaso-
pressin synthesized in the hypothalamus does not reach 
the posterior pituitary. The absence of a normal PBS in 
these cases is often accompanied by an ectopic bright spot 
due to the storage of vasopressin granules in another ana-
tomical location. A patient with pituitary dwarfism was 
found to have an absent PBS with an ectopic bright spot.24 
Acquired section of the pituitary stalk of traumatic or sur-
gical origin has also been found to result in an absent PBS 
and ectopic bright spot.10
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Object. The normal pituitary bright spot seen on unenhanced T1-weighted MRI is thought to result from the T1-
shortening effect of the vasopressin stored in the posterior pituitary. Individual variations in its size may be difficult to 
differentiate from pathological conditions resulting in either absence of the pituitary bright spot or in T1-hyperintense 
lesions of the sella. The objective of this paper was to define a range of normal dimensions of the pituitary bright 
spot and to illustrate some of the most commonly encountered pathologies that result in absence or enlargement of 
the pituitary bright spot.
Methods. The authors selected normal pituitary MRI studies from 106 patients with no pituitary abnormality. 
The size of each pituitary bright spot was measured in the longest axis and in the dimension perpendicular to this axis 
to describe the typical dimensions. The authors also present cases of patients with pituitary abnormalities to highlight 
the differences and potential overlap between normal and pathological pituitary imaging.
Results. All of the studies evaluated were found to have pituitary bright spots, and the mean dimensions were 
4.8 mm in the long axis and 2.4 mm in the short axis. The dimension of the pituitary bright spot in the long axis de-
creased with patient age. The distribution of dimensions of the pituitary bright spot was normal, indicating that 99.7% 
of patients should have a pituitary bright spot measuring between 1.2 and 8.5 mm in its long axis and between 0.4 
and 4.4 mm in its short axis, an interval corresponding to 3 standard deviations below and above the mean. In cases 
where the dimension of the pituitary bright spot is outside this range, pathological conditions should be considered.
Conclusions. The pituitary bright spot should always be demonstrated on T1-weighted MRI, and its dimensions 
should be within the identified normal range in most patients. Outside of this range, pathological conditions affecting 
the pituitary bright spot should be considered.
(http://thejns.org/doi/abs/10.3171/2013.11.JNS131320)
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A large area of T1 hyperintensity is seen in a number 
of pathologies resulting in accumulation of blood, mate-
rial with high protein content, or fat—all substances with 
a high T1 signal. Some of the most common lesions caus-
ing high T1 signal in the sella include Rathke’s cleft cysts 
and hemorrhagic pituitary adenomas. Other, less common 
causes of sellar T1 hyperintensity include abscesses, cho-
lesterol granulomas, dermoid cysts, and lipomas.2
When evaluating T1-weighted images of the pituitary 
gland, there is a need to define what is a normal PBS and 
what is a T1 hyperintensity that is outside of the spectrum 
of normal anatomy. The objective of this paper is to define 
a range of normal dimensions for the PBS in healthy sub-
jects and illustrate some of the most commonly encoun-
tered pathologies that result in absence or enlargement of 
the pituitary bright spot. By identifying the normal range, 
it is hoped that pathology of the pituitary gland may be 
more easily recognized. Examples of abnormal sellar T1 
hyperintense lesions will be discussed to illustrate the ap-
plication of this normal range and to demonstrate that pa-
thology should be recognized with alterations in the nor-
mal appearance.
Methods
After receiving institutional review board approval, 
we reviewed all of the dedicated pituitary MRI scans done 
from April 2011 to September 2012. Those studies that 
were interpreted as normal by a neuroradiologist were se-
lected for the study. We excluded pregnant women, as well 
as patients who had previous sellar or anterior skull base 
surgery.
The imaging protocol consisted of high-resolution 
MRI of the sella with sagittal and coronal T1-weighted, 
coronal T2-weighted, coronal dynamic contrast-enhanced 
T1-weighted, and postcontrast sagittal and coronal T1-
weighted images with fat saturation. All studies were per-
formed using a Siemens 1.5-T magnet with 3-mm slices or 
a Siemens 3-T magnet with 2.5-mm slices.
The PBS was identified on thin-slice sagittal T1-
weighted images. For a given patient, the slice on which 
the PBS was the largest was selected for measurements, 
even if this slice was not perfectly midline. To ensure 
that the hyperintense structure to be measured was pitu-
itary tissue and not clival bone marrow, the image was 
compared with the corresponding enhanced sagittal T1-
weighted image with fat saturation. The craniocaudal di-
mension of the PBS was measured along its longest axis, 
and the anteroposterior dimension was measured perpen-
dicular to this long axis (Fig. 1). The measurements were 
independently made by a neuroradiologist, a neurosurgery 
fellow, and a junior neurosurgery resident. In cases in 
which a measurement differed by more than 30% among 
the reviewers, a consensus was reached through discus-
sion among the three. For purposes of statistical analysis, 
the measurements used for each individual patient were 
the means of the measurements made by the neuroradiolo-
gist, the fellow, and the resident.
Results
A total of 106 MRI studies were selected for the 
study. There were 64 female (60%) and 42 male patients, 
and their mean age was 40.3 years (range 13–77 years). 
The indications for imaging were clinical or biochemical 
evidence of endocrine dysfunction (56%), suspicion of a 
pituitary lesion on another imaging modality (24%), head-
aches (11%), history of malignancy (usually melanoma; 
5%), or histiocytosis (1%). In 2 cases, no indication for pi-
tuitary imaging was specified.
The results of the measurements are summarized in 
Table 1. The mean (± SD) dimensions of the PBS were 4.8 
± 1.2 mm (range 1.7–7.8 mm) in the long axis and 2.4 ± 
0.7 mm (range 0.9–3.9 mm) in the short axis. A PBS was 
identified in all patients, and in 68% of cases the PBS was 
in the midline.
To confirm that the sample followed a normal distri-
bution, a Shapiro-Wilk test was performed. The test sta-
tistic result was 0.624 for the long-axis measurements and 
0.596 for the short-axis measurements, both greater than 
the 0.05 value chosen for the alpha level. This confirms 
that the data were normally distributed.
In a normal distribution, 99.7% of samples are within 
± 3 standard deviations of the mean. Applied to our mea-
surements, this rule means that the upper and lower limits 
are 8.5 mm and 1.2 mm for the long axis, respectively, and 
4.4 mm and 0.4 mm for the short axis, respectively.
Using multivariate regression, a significant inverse 
linear relationship was found between the long-axis di-
mension and the age of the subject (p = 0.042), but no sig-
nificant relationship was found between the long-axis di-
mension and sex of the subject (p = 0.088) or between the 
short-axis dimension and either age or sex of the subject 
(p = 0.401 and 0.277, respectively).
Fig. 1. Sample sagittal T1-weighted MR image showing the long and 
short axes of the PBS as measured on the PACS (picture archiving 
and communication system) workstation. The long craniocaudal axis is 
measurement A; measurement B is the perpendicular anteroposterior 
axis.
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Illustrative Case 1: Rathke’s Cleft Cyst
A 35-year-old woman underwent a pituitary MRI 
study as part of a workup for partial hypopituitarism. The 
images revealed a T1-hyperintense rounded area in the 
posterior sella measuring 9.0 × 5.0 mm (Fig. 2). Differ-
ential diagnosis included a normal PBS, a Rathke’s cleft 
cyst, or a hemorrhagic pituitary adenoma. The large di-
mensions of the T1-hyperintense area argued against a 
normal PBS. Given this, and the fact that the patient was 
symptomatic from a low cortisol level and was on thy-
roid hormone replacement, transsphenoidal exploration 
of the sella was performed, and a Rathke’s cleft cyst was 
found and drained. After surgery, the patient’s symptoms 
improved; however, she was still receiving hydrocortisone 
replacement therapy 6 months after surgery.
In this case, the T1-hyperintense lesion was situated 
where the PBS would be expected. Since the patient’s 
symptoms and her laboratory abnormalities could have 
been attributed to a number of causes, knowing the ex-
pected normal dimensions of the PBS could assist with 
the surgical decision making in such a situation.
Illustrative Case 2: Hemorrhagic Adenoma
A 21-year-old woman presented with galactorrhea 
and headaches. Her prolactin level was mildly elevated at 
47 ng/ml, and her MRI study showed a T1-hyperintense 
lesion measuring 7.0 × 5.5 mm (Fig. 3). In the clinical con-
text, the lesion was diagnosed as a hemorrhagic pituitary 
adenoma causing elevation of the prolactin level by pitu-
itary stalk compression. The patient elected radiological 
and endocrinological follow-up.
The presentation of a hemorrhagic pituitary adenoma 
can vary from acute onset of headache and visual distur-
bance to a more protracted course like in this patient. In 
these cases, it is important to correctly identify a hemor-
rhagic pituitary adenoma despite mild symptoms so that 
adequate follow-up is ensured.
Illustrative Case 3: Langerhans Cell Histiocytosis
A 36-year-old man recently diagnosed with diabetes 
mellitus underwent MRI, which showed mild thickening 
of the pituitary stalk and failed to demonstrate a PBS (Fig. 
4A). Six months later, the patient presented with increas-
ing somnolence; a second pituitary MRI study revealed 
a large, enhancing suprasellar mass (Fig. 4B and C). A 
stereotactic biopsy of the mass revealed an inflammatory 
infiltrate consistent with Langerhans cell histiocytosis. 
After the biopsy, the patient developed DI that required 
prolonged treatment with desmopressin. Of note, 5 years 
prior to this episode, the patient had undergone a biopsy 
for a bony lesion of the mandible that was confirmed to 
TABLE 1: Size of the pituitary bright spot in patients who 
underwent pituitary imaging
Dimension (mm)




mean − 3 SDs 1.2 0.4
mean + 3 SDs 8.5 4.4
Fig. 2. Illustrative Case 1. Sagittal T1-weighted MR image obtained 
without contrast enhancement in a 35-year-old woman presenting with 
partial hypopituitarism showing a T1-hyperintense region in the pituitary 
sella measuring 9.0 × 5.0 mm. The lesion was found to be a Rathke’s 
cleft cyst at resection.
Fig. 3. Illustrative Case 2. Sagittal T1-weighted MR image obtained 
without contrast enhancement in a 21-year-old woman who presented 
with headache and mild hyperprolactinemia showing a T1-hyperintense 
lesion in the sella measuring 7.0 × 5.5 mm. The clinical diagnosis was 
hemorrhagic microadenoma.
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be Langerhans cell histiocytosis. The patient was treated 
with chemotherapy after the suprasellar lesion biopsy.
Enlargement of the infundibulum and the absence of 
a PBS are the most typical features of Langerhans cell 
histiocytosis on pituitary MRI13,18 and can predate the 
onset of DI by several months.14 As discussed, an absent 
PBS should alert the clinician to the possibility of a patho-
logical condition; in this case, a history of a bony lesion 
diagnosed as Langerhans cell histiocytosis was an addi-
tional clue toward recognizing the central nervous system 
involvement by this disease.
Illustrative Case 4: Germinoma
A 14-year-old female patient was investigated for sec-
ondary amenorrhea. Her workup showed a mildly elevat-
ed prolactin level at 43 ng/ml; her other endocrine param-
eters were in normal ranges. This prompted us to obtain a 
pituitary MRI study, which demonstrated a homogeneous-
ly enhancing sellar and suprasellar mass. The PBS could 
not be identified on the T1-weighted image (Fig. 5). A 
partial resection of the lesion was performed through the 
transsphenoidal approach, and pathological examination 
confirmed the diagnosis of a germinoma. The patient was 
subsequently treated with chemotherapy and radiotherapy, 
with complete radiological response.
The differential diagnosis for this patient also includ-
ed pituitary adenoma, which is the most common mass 
lesion in the sella; however, a PBS can be identified in 
80%–81% of patients with a pituitary adenoma3,20 and in 
93% of cases when the adenoma is < 20 mm.3 Conversely, 
in germinomas, the PBS is noted to be absent in 100% of 
cases, whether the patient presents with DI or not.9 Fail-
ure to demonstrate a PBS in the context of a sellar and 
suprasellar mass should therefore prompt the clinician to 
consider the possibility of a germinoma, as well as other 
diagnoses associated with this feature.
Discussion
The PBS is a normal radiological finding that is be-
lieved to correspond to the neurohypophysis. We found 
that, in 99.7% of cases, the PBS should measure between 
1.2 mm and 8.5 mm in its longest axis and between 0.4 
mm and 4.4 mm in the axis perpendicular to the longest 
axis. When the PBS is found to exceed these dimensions 
in one or both axes, the physician should consider that the 
hyperintense signal observed may be an indication of a 
pathological process (although in 0.15% of individuals 
without pituitary disease the PBS can also exceed these 
measurements). Similarly, when the T1-hyperintense sig-
nal of the posterior pituitary is absent or below the lower 
limits, a pathological cause should be considered, as only 
0.15% of studies obtained in patients without pituitary dis-
ease should fall within this range.
Ju et al.16 investigated the normal dimensions of the 
neurohypophysis in a series of 33 autopsy cases. The di-
mensions were measured in the craniocaudal and antero-
posterior axes instead of along the longest and perpendic-
ular axes. The authors found that the mean values for the 
vertical and horizontal dimensions were 5.8 mm and 2.9 
mm, respectively. These dimensions are approximately 
20% longer than our findings; this may be explained by the 
fact that the neurohypophysis is an anatomical structure 
that is larger than the region dense in vasopressin granules 
that is seen as a hyperintense signal on T1-weighed MRI.1
In a study of 60 normal subjects (30 men and 30 wom-
en), the dimensions of the PBS on T1-weighted and proton 
density MRI were found to be 4.1 ± 1.6 mm for men and 
5.3 ± 1.0 mm for women along the craniocaudal axis and 
3.1 ± 0.9 mm (men) and 3.6 ± 0.8 mm (women) along the 
anteroposterior axis.8 Our finding of an average long-axis 
dimension of 4.8 mm seems to be in agreement with these 
authors’ conclusions; we also observed a trend toward 
larger PBSs in women along the long axis, although the 
difference was not statistically significant. Our average 
dimension along the short axis is 40% smaller than that of 
Fujisawa et al.8 This discrepancy may be explained by the 
fact that the patients were younger in that study (mean age 
of 25.3 years) and that the measurements were performed 
on proton density images.
The dimensions of the posterior pituitary gland were 
also investigated with thin-section CT in a series of 320 
patients. It could be identified in only 39% of patients, and 
when identified, appeared as a hypodense region measur-
ing 5–6 mm × 3–4 mm in all cases.4 Taking into account 
the differences between CT and MRI, these measure-
ments are also comparable with our own results.
We have not included the volume of the PBS in our 
study. Other authors who have investigated the appearance 
and size of the PBS on MRI have also reported only linear 
Fig. 4. Illustrative Case 3. A: Sagittal T1-weighted MR image obtained without contrast enhancement in a 36-year-old man 
6 months before his presentation with altered mental status. This image showed no PBS. B and C: Sagittal T1-weighted MR 
images obtained without (B) and with (C) contrast enhancement at the time of the patient’s presentation with altered mental status 
revealing a large, enhancing suprasellar mass. Biopsy demonstrated Langerhans cell histiocytosis.
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dimensions because the small size of the PBS results in 
inaccurate volume measurements.8 Moreover, linear mea-
surements are more commonly used in clinical practice 
when the question of differentiating a large PBS from an 
abnormal T1-hyperintense lesion of the sella occurs.
We identified a PBS in 100% of the patients whose 
studies we evaluated. The rate of detection of a PBS in 
normal adult subjects varies from 52% to 100%,5,6,8,23 but 
the direction of the frequency encoding gradient (FEG) 
was found to have an impact on the rate of detection. 
When the FEG direction was anteroposterior, the PBS 
was detected in 100% of cases in one study, whereas it 
was detected in only 54% of cases when it was directed 
caudocephalad.22 In our study, the sagittal T1-weighted 
images were obtained with an anteroposterior phase-en-
coding direction and a caudocephalad FEG direction; we 
are therefore unable to confirm whether the direction of 
the FEG has an impact on the rate of detection of the PBS. 
The fact that the PBS was detected in all of our cases, 
however, combined with the results of our analysis show-
ing that 99.85% of all pituitary MRIs should show a PBS 
with dimensions of at least 1.2 mm in the long axis and 
0.4 mm in the short axis, suggests that the true absence of 
a PBS on a good-quality pituitary MRI should prompt the 
investigation for a pathological cause.
We have also found that the size of the PBS decreases 
with age. In other studies, the rate of detection of the PBS 
decreased with patient age;5,23 it was hypothesized that 
the higher plasma osmolality in older subjects leads to in-
creased release of vasopressin, resulting in the disappear-
ance of the PBS. We believe that, instead of disappearing, 
the PBS becomes smaller as less vasopressin is stored in 
the posterior pituitary, which leads to the decrease of the 
PBS size with patient age that was observed in our study.
We assumed that the population included in this study 
was representative of the general population. This may be 
a limitation, as all of our patients had an indication to un-
dergo pituitary imaging—most often endocrine abnormal-
ities or suspicion of a pituitary lesion on another imaging 
modality. Nevertheless, we believe that our population is 
representative of the population of patients who undergo 
pituitary imaging, to whom the results of this study are 
meant to be applied.
Conclusions
We determined that, in 99.7% of cases, a PBS should 
be identifiable and should measure between 1.2 and 8.5 
mm in the long axis and between 0.4 and 4.4 mm in the 
short axis in patients who do not have any pituitary abnor-
mality. The dimension of the PBS in the long axis should 
be expected to decrease with patient age. When the size of 
the region of T1 signal hyperintensity in the sella is outside 
this range, or when the PBS is absent altogether, the clini-
cian should consider a pathological cause such as those 
discussed above.
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